313 related articles for article (PubMed ID: 26752541)
21. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis.
Shin YE; Rojanasarot S; Hincapie AL; Guo JJ
Sex Med; 2023 Oct; 11(5):qfad059. PubMed ID: 38034088
[TBL] [Abstract][Full Text] [Related]
22. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
Limin M; Johnsen N; Hellstrom WJ
Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743
[TBL] [Abstract][Full Text] [Related]
23. Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview.
Mostafa T; Alghobary M; Hanafy NS; Abosief A
Sex Med Rev; 2023 Jun; 11(3):240-252. PubMed ID: 36990971
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Min KS; Park K; Park JK
Eur Urol; 2011 Aug; 60(2):380-7. PubMed ID: 21458153
[TBL] [Abstract][Full Text] [Related]
25. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.
Porst H; Gacci M; Büttner H; Henneges C; Boess F
Eur Urol; 2014 Feb; 65(2):455-64. PubMed ID: 24119319
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials.
Sperling H; Gittelman M; Norenberg C; Ulbrich E; Ewald S
J Sex Med; 2011 Jan; 8(1):261-71. PubMed ID: 20807322
[TBL] [Abstract][Full Text] [Related]
27. Avanafil for the treatment of erectile dysfunction.
Zurawin JL; Stewart CA; Anaissie JE; Yafi FA; Hellstrom WJ
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1163-70. PubMed ID: 27416913
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials.
Du W; Li J; Fan N; Shang P; Wang Z; Ding H
Aging Male; 2014 Jun; 17(2):107-11. PubMed ID: 24219508
[TBL] [Abstract][Full Text] [Related]
29. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus.
Moon du G; Yang DY; Lee CH; Ahn TY; Min KS; Park K; Park JK; Kim JJ
J Sex Med; 2011 Jul; 8(7):2048-61. PubMed ID: 21554549
[TBL] [Abstract][Full Text] [Related]
30. Medical treatment of erectile dysfunction: too many medical prescriptions?
Capogrosso P; Ventimiglia E; Oreggia D; Salonia A; Montorsi F
Urologia; 2017 Aug; 84(3):121-129. PubMed ID: 28708203
[TBL] [Abstract][Full Text] [Related]
31. Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database.
DE Nunzio C; Nacchia A; Grimaldi MC; Turchi B; Rovesti L; Franco A; Guarnotta G; Voglino O; Mancini E; Baldassarri V; Lombardo R; Cicione A; Tubaro A
Minerva Urol Nephrol; 2024 Apr; 76(2):203-209. PubMed ID: 38498298
[TBL] [Abstract][Full Text] [Related]
32. A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction.
Cho MC; Paick JS
Ther Adv Urol; 2016 Apr; 8(2):100-17. PubMed ID: 27034723
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Hatzimouratidis K; Salonia A; Adaikan G; Buvat J; Carrier S; El-Meliegy A; McCullough A; Torres LO; Khera M
J Sex Med; 2016 Apr; 13(4):465-88. PubMed ID: 27045254
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study.
Ortaç M; Çayan S; Çalişkan MK; Yaman MÖ; Okutucu TM; Semerci MB; Altay AB; Balbay MD; Özcan MF; Kadioğlu A
Andrology; 2013 Jul; 1(4):549-55. PubMed ID: 23785019
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus.
Hamidi Madani A; Asadolahzade A; Mokhtari G; Shahrokhi Damavand R; Farzan A; Esmaeili S
J Sex Med; 2013 Apr; 10(4):1146-50. PubMed ID: 23347176
[TBL] [Abstract][Full Text] [Related]
36. Avanafil for the treatment of erectile dysfunction. An updated review.
Egui-Rojo MA; Moncada-Iribarren I; Carballido-Rodríguez J; Martínez-Salamanca JI
Arch Esp Urol; 2014 Dec; 67(10):839-47. PubMed ID: 25582903
[TBL] [Abstract][Full Text] [Related]
37. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
Lowe G; Costabile RA
J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: a review of literature.
Rizio N; Tran C; Sorenson M
J Spinal Cord Med; 2012 Jul; 35(4):219-28. PubMed ID: 22925748
[TBL] [Abstract][Full Text] [Related]
39. Avanafil for treatment of erectile dysfunction: review of its potential.
Burke RM; Evans JD
Vasc Health Risk Manag; 2012; 8():517-23. PubMed ID: 22973106
[TBL] [Abstract][Full Text] [Related]
40. Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction.
Gao L; Yang L; Qian S; Li T; Han P; Yuan J
Int J Gynaecol Obstet; 2016 May; 133(2):139-45. PubMed ID: 26797204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
